Apple To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Tuesday
Portfolio Pulse from Lisa Levin
Several analyst firms have updated their price targets and ratings for various US-listed companies, including Apple, Adobe, Castle Biosciences, Sprinklr, Dollar General, FedEx, GitLab, KB Home, Ultragenyx Pharmaceutical, SPX Technologies, and Molson Coors Beverage.
June 06, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo raised Apple's price target from $185 to $210, maintaining an Overweight rating.
The increased price target by Wells Fargo suggests a positive outlook for Apple's stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Barclays increased Adobe's price target from $385 to $485, maintaining an Overweight rating.
The increased price target by Barclays indicates a positive outlook for Adobe's stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Morgan Stanley raised Sprinklr's price target from $14 to $16, maintaining an Equal-Weight rating.
The increased price target by Morgan Stanley suggests a positive outlook for Sprinklr's stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
JP Morgan boosted GitLab's price target from $33 to $39, maintaining a Neutral rating.
The increased price target by JP Morgan suggests a positive outlook for GitLab's stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Goldman Sachs raised KB Home's price target from $44 to $49, maintaining a Buy rating.
The increased price target by Goldman Sachs suggests a positive outlook for KB Home's stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Evercore ISI Group boosted Ultragenyx Pharmaceutical's price target from $60 to $80, upgrading the stock from In-Line to Outperform.
The increased price target and upgraded rating by Evercore ISI Group suggest a positive outlook for Ultragenyx Pharmaceutical's stock. This could lead to a short-term increase in the stock price as investors react to the updated target and rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Oppenheimer increased SPX Technologies' price target from $85 to $92, maintaining an Outperform rating.
The increased price target by Oppenheimer suggests a positive outlook for SPX Technologies' stock. This could lead to a short-term increase in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
B of A Securities boosted Molson Coors Beverage's price target from $54 to $68, upgrading the stock from Underperform to Neutral.
The increased price target and upgraded rating by B of A Securities suggest a positive outlook for Molson Coors Beverage's stock. This could lead to a short-term increase in the stock price as investors react to the updated target and rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Canaccord Genuity cut Castle Biosciences' price target from $60 to $40, maintaining a Buy rating.
The reduced price target by Canaccord Genuity suggests a negative outlook for Castle Biosciences' stock. This could lead to a short-term decrease in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Wells Fargo cut Dollar General's price target from $178 to $165, maintaining an Equal-Weight rating.
The reduced price target by Wells Fargo suggests a negative outlook for Dollar General's stock. This could lead to a short-term decrease in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
JP Morgan cut FedEx's price target from $233 to $228, maintaining a Neutral rating.
The reduced price target by JP Morgan suggests a negative outlook for FedEx's stock. This could lead to a short-term decrease in the stock price as investors react to the updated target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100